Skip to main content

A GlaxoSmithKline logo on one of its buildings in west London in February 2008.

Toby Melville/Reuters

A B.C. Supreme Court judge has ruled a class-action lawsuit can go ahead against the maker of the antidepressant drug Paxil.

The allegations against GlaxoSmithKline Inc. are that the drug caused birth defects in children whose mothers used it during pregnancy.

The representative plaintiff in the case, Faith Gibson, says she started using the drug in 2002 and continued using it when she was pregnant through 2005, when her daughter Meah was born and later diagnosed with a hole in her heart.

Story continues below advertisement

Paxil issued a warning in September of 2004 regarding respiratory complications in newborns whose mothers used Paxil during the third trimester of pregnancy.

It is unclear how many people will join the lawsuit, but evidence put forward during the application asking for approval of the class action says almost six million Paxil prescriptions were written for women of child-bearing age between 1993 and 2009.

While the case still needs to go to trial, Mr. Justice Nathan Smith ruled there are enough common issues in the case to warrant a class-action proceeding.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter